Trade Arcus Biosciences, Inc. - RCUS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.17 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001096% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.05 |
| Open | 7.92 |
| 1-Year Change | -48.77% |
| Day's Range | 7.92 - 8.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 8.33 | 0.41 | 5.18% | 7.92 | 8.43 | 7.92 |
| Apr 23, 2025 | 8.05 | -0.07 | -0.86% | 8.12 | 8.45 | 8.01 |
| Apr 22, 2025 | 8.04 | 0.38 | 4.96% | 7.66 | 8.09 | 7.66 |
| Apr 21, 2025 | 7.59 | 0.06 | 0.80% | 7.53 | 7.95 | 7.53 |
| Apr 17, 2025 | 7.83 | 0.24 | 3.16% | 7.59 | 7.91 | 7.59 |
| Apr 16, 2025 | 7.80 | 0.05 | 0.65% | 7.75 | 7.95 | 7.51 |
| Apr 15, 2025 | 7.90 | 0.48 | 6.47% | 7.42 | 7.97 | 7.41 |
| Apr 14, 2025 | 7.62 | -0.52 | -6.39% | 8.14 | 8.20 | 7.44 |
| Apr 11, 2025 | 8.11 | 0.82 | 11.25% | 7.29 | 8.11 | 7.20 |
| Apr 10, 2025 | 7.45 | 0.11 | 1.50% | 7.34 | 7.55 | 7.04 |
| Apr 9, 2025 | 7.90 | 1.17 | 17.38% | 6.73 | 8.06 | 6.71 |
| Apr 8, 2025 | 7.00 | -0.28 | -3.85% | 7.28 | 7.48 | 6.81 |
| Apr 7, 2025 | 7.20 | 0.79 | 12.32% | 6.41 | 7.34 | 6.41 |
| Apr 4, 2025 | 6.61 | -0.40 | -5.71% | 7.01 | 7.24 | 6.61 |
| Apr 3, 2025 | 7.13 | -0.34 | -4.55% | 7.47 | 7.57 | 7.07 |
| Apr 2, 2025 | 7.80 | 0.35 | 4.70% | 7.45 | 7.87 | 7.44 |
| Apr 1, 2025 | 7.66 | -0.03 | -0.39% | 7.69 | 7.84 | 7.43 |
| Mar 31, 2025 | 7.80 | -0.01 | -0.13% | 7.81 | 7.94 | 7.46 |
| Mar 28, 2025 | 8.12 | -0.29 | -3.45% | 8.41 | 8.48 | 8.04 |
| Mar 27, 2025 | 8.42 | 0.26 | 3.19% | 8.16 | 8.47 | 8.06 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Arcus Biosciences, Inc. Company profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company''s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.| Industry: | Biotechnology & Medical Research (NEC) |
3928 Point Eden Way
HAYWARD
CALIFORNIA 94545-3719
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com